OTC Monographs Finalized In 81% Of Categories
This article was originally published in The Tan Sheet
Of the 52 monograph categories in FDA’s OTC Drug Review, 81% have a final monograph, including negative, according to CHPA’s latest summary.
You may also be interested in...
The EU is pulling out all the stops to have the one-year delay to the MDR adopted before it is too late, and a crucial vote will take place on 16 April.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Virtual notified body audits of medtech manufacturers are already taking place through necessity. Now there is guidance concerning if, when, where and how these audits should be carried out.